In what is believed to be the first study of its kind to examine the relationship between pre-existing depression (with and without anxiety ) and the amount of time to diagnostically resolve an abnormal mammogram and/or Pap test, researchers from Boston University School of Medicine (BUSM) have found suffering from depression was not associated with a prolonged time to diagnostic resolution in a vulnerable population of urban women. These findings currently appear in the Journal of General Internal Medicine. Delays in care after abnormal cancer screenings contribute to disparities in cancer out- comes. Women with psychiatric disorders are less likely to receive cancer screening and may also have delays in diagnostic resolution after an abnormal screening test. Vulnerable populations of women, as defined by low income or with racial/ethnic minority status, are less likely to receive standard preventive health care, which contributes to worse breast and cervical cancer outcomes.
According to an investigation recently published online in The Lancet Oncology, data from a sub-analysis of the Addressing THE Need for Advanced HPV Diagnostics (ATHENA) landmark study, showed that the HPV test Roche cobas, may be used for initial screening of cervical cancer. Furthermore, data from the study demonstrated that vital predictive information in determining a woman's risk of cervical cancer was provided by identifying women with HPV 16 and/or 18 (the two genotypes identified in around 70% of cervical cancers). Cytology testing (Pap test) is allowed in order to determine the risk of cervical cancer by current cervical cancer screening guidelines. However, according to data, cervical cancer was identified at a higher rate using HPV DNA testing as primary (first-line) screening than cytology alone.
BSD Medical Corporation's new system of using heat to treat cancer, known as the BSD-2000 Hyperthermia System, which uses "hyper" not "hypo" thermia, has been granted Humanitarian Device Exemption (HDE) marketing approval from the U.S. Food and Drug Administration (FDA). The BSD-2000 is especially useful for cervical cancer patients that are unable to withstand chemotherapy, or are ineligible for other reasons. They can be treated with radiation and heat alone. The purpose of the HDE is to allow these small number of patients use of the device before as quickly as possible. HDE's are granted where the disease affects fewer than 4000 people per year. Harold Wolcott, CEO of BSD Medical, stated : "We are excited to reach this significant milestone in BSD's history and obtain marketing approval for the BSD-2000 Hyperthermia System.
The GAVI Alliance Board is to move towards the vaccination of up to two million girls and women in nine countries against HPV (human papillomavirus) and rubella over the next four years. GAVI is a charity which aims to save children's lives and protect people's health "by increasing access to immunization in poor countries". GAVI's Board members said that if a realistically sustainable price can be successfully reached with vaccine makers, and the targeted developing nations can show they are able to deliver the vaccines, approximately two million females could be protected from cervical cancer within the next four years. Rwanda and Vietnam are probably going to be the first countries to vaccinate their girls and women, because they have carried out pilot vaccination programs. The other seven countries will be announced soon.
Cancer cells maintain their life-style of extremely rapid growth and proliferation thanks to an enzyme called PK-M2 (pyruvate kinase M2) that alters the cells' ability to metabolize glucose - a phenomenon known as the Warburg effect. Professor Adrian Krainer, Ph.D., and his team at Cold Spring Harbor Laboratory (CSHL), who seek to reverse this effect and force cancer cells to regain the metabolism of normal cells, have discovered details of molecular events that cause cancer cells to produce PK-M2 instead of its harmless counterpart, an isoform called PK-M1. Their study, performed in collaboration with Professor Lewis Cantley, Ph.D., and his colleagues at Harvard Medical School and The Koch Institute, in Cambridge, Mass, appeared in the Journal of Molecular Cell Biology. Both protein isoforms - PK-M2 and PK-M1, the latter of which is found only in normal cells - are both encoded by the same gene, PK-M, in a mutually exclusive fashion via a process called alternative splicing.